Lee S. Schwartzberg, MD, on HR+ Breast Cancer: Treatment Trial Results

2017 San Antonio Breast Cancer Symposium
Tweet this page

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase II study findings evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer (Abstract GS4-07).

Advertisement

Advertisement



Advertisement